Human Serum Albumin-Coated

boron neutron capture therapy boron‐containing carbon dots human serum albumin tumor targeting

Journal

Advanced science (Weinheim, Baden-Wurttemberg, Germany)
ISSN: 2198-3844
Titre abrégé: Adv Sci (Weinh)
Pays: Germany
ID NLM: 101664569

Informations de publication

Date de publication:
26 Sep 2024
Historique:
revised: 10 09 2024
received: 13 06 2024
medline: 26 9 2024
pubmed: 26 9 2024
entrez: 26 9 2024
Statut: aheadofprint

Résumé

Boron neutron capture therapy (BNCT) is a physiologically focused radiation therapy that relies on nuclear capture and fission processes. BNCT is regarded as one of the most promising treatments due to its excellent accuracy, short duration of therapy, and low side effects. The creation of novel boron medicines with high selectivity, ease of delivery, and high boron-effective load is a current research topic. Herein, boron-containing carbon dots (BCDs) and their human serum albumin (HSA) complexes (BCDs-HSA) are designed and synthesized as boron-containing drugs for BNCT. BCDs (

Identifiants

pubmed: 39324650
doi: 10.1002/advs.202406577
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2406577

Subventions

Organisme : Projects of Jilin Province Science and Technology Development Plan
ID : 20240101273JC
Organisme : Shenzhen Science and Technology Program
ID : JCYJ20230807112801003
Organisme : Fundamental Research Funds for the Central Universities-Excellent Youth Team Program
ID : 2412023YQ001
Organisme : National Natural Science Foundation of China
ID : 52273124
Organisme : National Natural Science Foundation of China
ID : 52103193
Organisme : Fundamental Research Funds for the Central Universities
ID : 2412023QD017

Informations de copyright

© 2024 The Author(s). Advanced Science published by Wiley‐VCH GmbH.

Références

L. Bodei, K. Herrmann, H. Schoeder, A. M. Scott, J. S. Lewis, Nat. Rev. Clin. Oncol. 2022, 19, 534.
P. Price, B. Fleurent, S. E. Barney, Int. J. Radiat. Oncol. Biol. Phys. 2021, 111, 23.
a) K. L. Pomykala, B. A. Hadaschik, O. Sartor, S. Gillessen, C. J. Sweeney, T. Maughan, M. S. Hofman, K. Herrmann, Ann. Oncol. 2023, 34, 507;
b) M. I. Khan, F. Batool, R. Ali, Q. u. A. Zahra, W. Wang, S. Li, G. Wang, L. Liu, S. U. Khan, M. Mansoor, M. Bilal, W. Ding, A. Kazmi, F. Li, B. Qiu, Coord. Chem. Rev. 2022, 472, 214757;
c) Y. Pan, W. Tang, W. Fan, J. Zhang, X. Chen, Chem. Soc. Rev. 2022, 51, 9759.
a) M. A. Dymova, S. Y. Taskaev, V. A. Richter, E. V. Kuligina, Cancer Commun (Lond) 2020, 40, 406;
b) Y. Sun, Mil. Med. Res. 2019, 6, 32;
c) I. Kato, Y. Fujita, N. Yamamoto, M. Ohmae, Y. Sakurai, M. Suzuki, S.‐i. Masunaga, I. Murata, M. Nakazawa, K. Ono, J. Clin. Oncol. 2016, 34.
a) K. Hirose, A. Konno, J. Hiratsuka, S. Yoshimoto, T. Kato, K. Ono, N. Otsuki, J. Hatazawa, H. Tanaka, K. Takayama, H. Wada, M. Suzuki, M. Sato, H. Yamaguchi, I. Seto, Y. Ueki, S. Iketani, S. Imai, T. Nakamura, T. Ono, H. Endo, Y. Azami, Y. Kikuchi, M. Murakami, Y. Takai, Radiother Oncol 2021, 155, 182;
b) A. Matsumura, T. Asano, K. Hirose, H. Igaki, S. Kawabata, H. Kumada, Cancer Biother. Radiopharm. 2023, 38, 201;
c) S.‐I. Miyatake, S. Kawabata, S. Takai, M. Wanibuchi, Neuro‐Oncology 2021, 23, vi194.
X. Sun, L. Wu, L. Du, W. Xu, M. Han, Asian J Pharm. Sci. 2024, https://doi.org/10.1016/j.ajps.2024.100903100903.
a) R. F. Barth, P. Mi, W. Yang, Cancer Commun (Lond) 2018, 38, 35;
b) K. Hu, Z. Yang, L. Zhang, L. Xie, L. Wang, H. Xu, L. Josephson, S. H. Liang, M.‐R. Zhang, Coord. Chem. Rev. 2020, 405, 213139.
a) P. Coghi, J. Li, N. S. Hosmane, Y. Zhu, Med Res Rev 2023, 43, 1809;
b) W. Chen, S. C. Mehta, D. R. Lu, Adv. Drug Delivery Rev. 1997, 26, 231;
c) K. Chen, S. Liu, L. Lv, J. Tong, J. Chen, H. Liang, Y. Wang, F. Hu, Q. Liu, H. Li, Z. Chen, J. Li, Z. Wang, Y.‐n. Chang, J. Li, H. Yuan, S. Fu, T. Liang, G. Xing, Nano Today 2023, 52, 101995;
d) Y. Shi, Z. Guo, Q. Fu, X. Shen, Z. Zhang, W. Sun, J. Wang, J. Sun, Z. Zhang, T. Liu, Z. Gu, Z. Liu, Nat. Commun. 2023, 14, 1884;
e) L. Dai, J. Liu, X. Zhao, Y. Li, S. Zhou, L. Yuan, D. Shu, L. Pan, Y. h. Liu, Z. Qian, Adv. Funct. Mater. 2023, 33.
a) X. Li, X. Peng, M. Zoulikha, G. F. Boafo, K. T. Magar, Y. Ju, W. He, Signal Transduct Target Ther 2024, 9, 1;
b) Q. Zhou, J. Xiang, N. Qiu, Y. Wang, Y. Piao, S. Shao, J. Tang, Z. Zhou, Y. Shen, Chem. Rev. 2023, 123, 10920;
c) X. Kong, Y. Qi, X. Wang, R. Jiang, J. Wang, Y. Fang, J. Gao, K. C. Hwang, Prog. Mater. Sci. 2023, 134, 101070.
a) Y. Pan, Y. Qi, X. Li, S. Luan, Y. Huang, Adv. Funct. Mater. 2021, 31;
b) Y. Wang, J. Yu, Z. Luo, Q. Shi, G. Liu, F. Wu, Z. Wang, Y. Huang, D. Zhou, Adv. Mater. 2021, 33, 2103497;
c) J. Yu, X. He, Q. Zhang, D. Zhou, Z. Wang, Y. Huang, ACS Nano 2022, 16, 6835.
a) B. Wang, H. Song, X. Qu, J. Chang, B. Yang, S. Lu, Coord. Chem. Rev. 2021, 442, 214010;
b) Y. Wang, X. Li, S. Zhao, B. Wang, X. Song, J. Xiao, M. Lan, Coord. Chem. Rev. 2022, 470, 214703;
c) K. K. Chan, S. H. K. Yap, K. T. Yong, Nanomicro Lett. 2018, 10, 72.
J. Li, J. Kong, S. Ma, J. Li, M. Mao, K. Chen, Z. Chen, J. Zhang, Y. Chang, H. Yuan, T. Liu, Z. Zhang, G. Xing, Adv. Funct. Mater. 2021, 31, 2100969.
a) G. J. Quinlan, G. S. Martin, T. W. Evans, Hepatology 2005, 41, 1211;
b) G. Fanali, A. di Masi, V. Trezza, M. Marino, M. Fasano, P. Ascenzi, Mol. Aspects. Med. 2012, 33, 209;
c) Z. Liu, X. Chen, Chem. Soc. Rev. 2016, 45, 1432.
a) Z. Shi, M. Luo, Q. Huang, C. Ding, W. Wang, Y. Wu, J. Luo, C. Lin, T. Chen, X. Zeng, L. Mei, Y. Zhao, H. Chen, Nat. Commun. 2023, 14, 6567;
b) K. Xu, P. Huang, Y. Wu, T. Liu, N. Shao, L. Zhao, X. Hu, J. Chang, Y. Peng, S. Qu, ACS Nano 2023, 17, 19961;
c) N. Desai, V. Trieu, B. Damascelli, P. Soon‐Shiong, Transl. Oncol. 2009, 2, 59;
d) A. Neesse, K. K. Frese, D. S. Chan, T. E. Bapiro, W. J. Howat, F. M. Richards, V. Ellenrieder, D. I. Jodrell, D. A. Tuveson, Gut. 2014, 63, 974.
a) W. J. Gradishar, Expert Opinion on Pharmacotherapy 2006, 7, 1041;
b) M. R. Green, G. M. Manikhas, S. Orlov, B. Afanasyev, A. M. Makhson, P. Bhar, M. J. Hawkins, Ann. Oncol. 2006, 17, 1263;
c) A. Al Housseini, P. Daugherty, M. Sofidiya, M. Burrell, J. Boverie, B. Benigno, J. Clin. Oncol. 2008, 26.
I. V. J. Feiner, K. R. Pulagam, K. B. Uribe, R. Passannante, C. Simo, K. Zamacola, V. Gomez‐Vallejo, N. Herrero‐Alvarez, U. Cossio, Z. Baz, M. M. Caffarel, C. H. Lawrie, D. J. Vugts, L. Rejc, J. Llop, J. Mater. Chem. B 2021, 9, 410.
J. Xu, Y. Guo, T. Gong, K. Cui, L. Hou, C. Yuan, Inorg. Chem. Commun. 2022, 145, 110047.
a) C. R. Park, J. H. Jo, M. G. Song, J. Y. Park, Y.‐H. Kim, H. Youn, S. H. Paek, J.‐K. Chung, J. M. Jeong, Y.‐S. Lee, K. W. Kang, Theranostics 2019, 9, 7447;
b) P. Hua, R. Liang, S. Yang, Y. Tu, M. Chen, Bioact Mater 2024, 36, 83.
G. P. Nagaraju, R. Dontula, B. F. El‐Rayes, S. S. Lakka, Carcinogenesis 2014, 35, 967.
X. Li, L. Zhao, Y. Wu, A. Zhou, X. Jiang, Y. Zhan, Z. Sun, Spectrochim Acta A Mol. Biomol. Spectrosc. 2022, 282, 121638.
Y. Qi, S. Jing, S. He, H. Xiong, G. Yang, Y. Huang, N. Jin, Nano Res. 2020, 14, 778.

Auteurs

Tianyuan Zhong (T)

Faculty of Chemistry, Northeast Normal University, Changchun, 130024, China.

Yongjin Yang (Y)

Department of Urology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, Gansu, 730000, China.
Gansu Province Clinical Research Center for Urinary System Disease, Lanzhou, Gansu, 730000, China.

Miao Pang (M)

Faculty of Chemistry, Northeast Normal University, Changchun, 130024, China.

Yong Pan (Y)

Faculty of Chemistry, Northeast Normal University, Changchun, 130024, China.

Shiwei Jing (S)

School of Physics, Northeast Normal University, Changchun, 130024, China.

Yanxin Qi (Y)

Faculty of Chemistry, Northeast Normal University, Changchun, 130024, China.

Yubin Huang (Y)

Faculty of Chemistry, Northeast Normal University, Changchun, 130024, China.

Classifications MeSH